Non-peptide δ opioid agonists and antagonists (Part II)

A continuing effort in the development of non-peptide δ opioid agonists and antagonists has been seen in the last two years. The first non-peptide δ opioid antagonist naltrindole has represented for years the starting point for the design of novel potent and selective δ opioid ligands. Several research groups are still working on the framework of this prototype and have produced a large number of new derivatives with different in vitro and in vivo pharmacological activities. The discovery of TAN-67, BW373U86 and SNC 80 stimulated other lines of research aimed at synthesising analogues with better δ opioid agonist profile and suitable in vivo activity. Chemically unrelated compounds have also been disclosed deriving from the structural comparison of previously identified ligands. These studies have given further insights about the key determinants for the selective interaction with the δ opioid receptor (DOR). The availability of these tool compounds has allowed significant progression in the understanding...

[1]  Kwen-Jen Chang,et al.  Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. , 1998, The Journal of pharmacology and experimental therapeutics.

[2]  P. Portoghese,et al.  Erratum: The σ1-opioid receptor antagonist, 7-benzylspiroindanylnaltrexone, prolongs renal allograft survival in a rat model (European Journal of Pharmacology 354 (1998) (R3-R5) PII: S0014299998004774) , 1998 .

[3]  V. Hruby,et al.  De Novo Design, Synthesis, and Biological Activities of High-Affinity and Selective Non-Peptide Agonists of the δ-Opioid Receptor‖ , 1998 .

[4]  A. Lipkowski,et al.  Inhibitory effect of biphalin and AZT on murine Friend leukemia virus infection in vitro. , 1998, International journal of immunopharmacology.

[5]  D. Kapusta,et al.  Renal excretory responses produced by the delta opioid agonist, BW373U86, in conscious rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[6]  P. Portoghese,et al.  Contribution of the opioid system to alcohol aversion and alcohol drinking behavior. , 1998, The Journal of pharmacology and experimental therapeutics.

[7]  A. Andrews,et al.  Delta opioid peptide [D-Ala2,D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: involvement of opioid receptors and reactive oxygen species. , 1998, The Journal of pharmacology and experimental therapeutics.

[8]  P. Portoghese,et al.  7-Arylidenenaltrexones as Selective δ1 Opioid Receptor Antagonists , 1998 .

[9]  M. Li,et al.  Delta-opioid suppression of human immunodeficiency virus-1 expression in T cells (Jurkat). , 1998, Biochemical pharmacology.

[10]  K. Rice,et al.  Rat natural killer cell, T cell and macrophage functions after intracerebroventricular injection of SNC 80. , 1998, The Journal of pharmacology and experimental therapeutics.

[11]  B. Roques,et al.  Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. , 1998, European journal of pharmacology.

[12]  P. Portoghese,et al.  The δ1-opioid receptor antagonist, 7-benzylspiroindanylnaltrexone, prolongs renal allograft survival in a rat model , 1998 .

[13]  D. L. Larson,et al.  Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors. , 1998, Journal of medicinal chemistry.

[14]  P. Portoghese,et al.  14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors. , 1998, Journal of medicinal chemistry.

[15]  K. Rice,et al.  Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. , 1998, Journal of medicinal chemistry.

[16]  G. Bepler,et al.  Molecular characterization of the human delta opioid receptor in lung cancer. , 1998, Anticancer research.

[17]  H. Kubota,et al.  Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives. , 1998, Bioorganic & medicinal chemistry letters.

[18]  A. Hsu,et al.  Ischemic Preconditioning in the Intact Rat Heart Is Mediated by δ1- But Not μ- or κ-Opioid Receptors , 1998 .

[19]  D. Rogers,et al.  Neuroregulation of mucus secretion by opioid receptors and KATP and BKCa channels in ferret trachea in vitro , 1998, British journal of pharmacology.

[20]  R. DesJarlais,et al.  Pyrrolooctahydroisoquinolines as Potent and Selective δ Opioid Receptor Ligands: SAR Analysis and Docking Studies. , 1998 .

[21]  Xiao-jun Xu,et al.  Treatment of chronic allodynia in spinally injured rats: effects of intrathecal selective opioid receptor agonists , 1998, Pain.

[22]  J. Cortijo,et al.  Binding of [3H][D-Ala2, MePhe4, Gly-ol5] Enkephalin, [3H][D-Pen2, D-Pen5]Enkephalin, and [3H]U-69,593 to Airway and Pulmonary Tissues of Normal and Sensitized Rats , 1997, Peptides.

[23]  R. DesJarlais,et al.  Pyrrolooctahydroisoquinolines as potent and selective ° opioid receptor ligands: SAR analysis and docking studies , 1997 .

[24]  D. Giulian Immune Responses and Dementia a , 1997, Annals of the New York Academy of Sciences.

[25]  G. Dondio,et al.  Non-peptide δ opioid agonists and antagonists , 1997 .

[26]  S Ronzoni,et al.  Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept. , 1997, Journal of medicinal chemistry.

[27]  D. L. Larson,et al.  7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands. , 1997, Journal of medicinal chemistry.

[28]  C. Perego,et al.  Interleukin-6 is differently modulated by central opioid receptor subtypes. , 1997, The American journal of physiology.

[29]  Koichi Homma,et al.  Probes for Narcotic Receptor-Mediated Phenomena. 25.1 Synthesis and Evaluation of N-Alkyl-Substituted (α-Piperazinylbenzyl)benzamides as Novel, Highly Selective δ Opioid Receptor Agonists , 1997 .

[30]  A. Hsu,et al.  Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. , 1997, Journal of molecular and cellular cardiology.

[31]  C. Gianoulakis,et al.  Characterization of the mu and delta opioid receptors in the brain of the C57BL/6 and DBA/2 mice, selected for their differences in voluntary ethanol consumption. , 1997, Alcoholism, clinical and experimental research.

[32]  C. Kuhn,et al.  Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[33]  D. L. Larson,et al.  7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors. , 1997, Journal of medicinal chemistry.

[34]  M. Misawa,et al.  Involvement of δ1 and δ2 Opioid Receptor Subtypes in the Development of Physical Dependence on Morphine in Mice , 1997, Pharmacology Biochemistry and Behavior.

[35]  G. Pasternak,et al.  Antisense mapping DOR-1 in mice: further support for δ receptor subtypes , 1997, Brain Research.

[36]  Z. Darula,et al.  Analysis of the role of delta opioid receptors in gastroprotection in the rat. , 1997, Life sciences.

[37]  R. Lesser,et al.  Imaging of δ‐ and μ‐opioid receptors in temporal lobe epilepsy by positron emission tomography , 1997 .

[38]  Robert Horvath,et al.  Probes for narcotic receptor mediated phenomena. 23.1 Synthesis, opioid receptor binding, and bioassay of the highly selective δ agonist (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and related novel nonpeptide δ opioid receptor ligands , 1997 .

[39]  H. Steiner,et al.  Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin , 1996, Nature.

[40]  J. Brotchie,et al.  Potential of Opioid Antagonists in the Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease , 1996, Drugs & aging.

[41]  T. Vanderah,et al.  Opioid receptor types and subtypes: the delta receptor as a model. , 1996, Annual review of pharmacology and toxicology.

[42]  M. J. Bishop,et al.  Characterization of δ Opioid Receptors in Lung Cancer Using a Novel Nonpeptidic Ligand , 1996 .

[43]  W. Klee,et al.  Agonist regulation of the expression of the delta opioid receptor in NG108‐15 cells , 1995, FEBS letters.

[44]  P. Levitt,et al.  Induction of opioid receptor-mediated macrophage chemotactic activity after neonatal brain injury. , 1995, Journal of immunology.

[45]  Stanley J. Watson,et al.  Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications , 1995, Trends in Neurosciences.

[46]  C. Stein,et al.  Perineurial defect and peripheral opioid analgesia in inflammation , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  G. Pasternak,et al.  An opiate-receptor gene family reunion , 1994, Trends in Neurosciences.

[48]  T. Su,et al.  Extension of tissue survival time in multiorgan block preparation with a delta opioid DADLE ([D-Ala2, D-Leu5]-enkephalin) , 1994, The Journal of thoracic and cardiovascular surgery.

[49]  T. Vanderah,et al.  Antinociceptive actions of BW373U86 in the mouse. , 1993, The Journal of pharmacology and experimental therapeutics.

[50]  A. Herz,et al.  Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue , 1993, Neuroscience.

[51]  V. Perry,et al.  Macrophages and inflammation in the central nervous system , 1993, Trends in Neurosciences.

[52]  J. Desmeules,et al.  Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain , 1993, Pain.

[53]  M. Zenz,et al.  Opiophobia and cancer pain in Europe , 1993, The Lancet.

[54]  R. Edwards,et al.  Cloning of a delta opioid receptor by functional expression. , 1992, Science.

[55]  K. Befort,et al.  The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[56]  A. Dickenson,et al.  Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation , 1992, PAIN.

[57]  P. Portoghese,et al.  A highly selective δ1-opioid receptor antagonist : 7-benzylidenenaltrexone , 1992 .

[58]  D. A. Thomas,et al.  Spinal opioid analgesic effects are enhanced in a model of unilateral inflammation/hyperalgesia: possible involvement of noradrenergic mechanisms. , 1991, European journal of pharmacology.

[59]  Chen Jianguo,et al.  A study on opioid peptides in CSF of patients with epilepsy , 1990, Epilepsy Research.

[60]  T. Shippenberg,et al.  Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. , 1989, The Journal of pharmacology and experimental therapeutics.

[61]  F. Tortella,et al.  Endogenous opioid peptides and epilepsy: quieting the seizing brain? , 1988, Trends in pharmacological sciences.

[62]  J. Holaday,et al.  Anticonvulsant effects of mu (DAGO) and delta (DPDPE) enkephalins in rats , 1988, Peptides.

[63]  J. Kotlinska,et al.  Audiogenic seizures during ethanol withdrawal can be blocked by a delta opioid agonist. , 1986, Drug and alcohol dependence.

[64]  C. Mcintosh,et al.  Autoradiographic Localization of μ- and δ-Type Opioid Receptors in the Gastrointestinal Tract of the Rat and Guinea Pig , 1986 .

[65]  M. Max,et al.  The analgesic efficacy of intrathecal d-ala2-d-leu5-enkephalin in cancer patients with chronic pain , 1985, Pain.

[66]  M. Trabucchi,et al.  Effect of naloxone on the "on-off' syndrome in patients receiving long-term levodopa therapy. , 1982, Archives of neurology.

[67]  W. Bunney,et al.  PLASMA OPIOID ACTIVITY IN MANIC-DEPRESSIVE ILLNESS , 1980, The Lancet.

[68]  S. Schultz,et al.  A century of (epithelial) transport physiology: from vitalism to molecular cloning. , 1998, The American journal of physiology.

[69]  J. Froehlich Genetic factors in alcohol self-administration. , 1995, The Journal of clinical psychiatry.